In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment
Cardiovascular Research · 28.10.2025 · 121 (13) · 2042-2054
DOI: 10.1093/cvr/cvaf156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 04.09.2025. Verfasst von Liu Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713 GZ, The Netherlands. Hauptthemen laut MEDLINE: Calcium-Binding Proteins, Myocytes, Cardiac, Sarcoplasmic Reticulum, Calcium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Heart Foundation, Fondation Leducq, PLN Foundation.
Abstract (Originalsprache)
Aims
Phospholamban (PLN) acts as an inhibitory regulator of calcium uptake in the sarco-/endoplasmic reticulum (SR) of cardiomyocytes. The pathogenic variant, PLN-R14del, leads to dilated and/or arrhythmogenic cardiomyopathy. Previous studies demonstrated that PLN-targeting antisense oligonucleotides (ASOs) can mitigate disease progression in mice. However, it remains unclear whether the protective effects of PLN-ASO therapy are due to improved calcium homeostasis or via reduction of abnormal PLN-SR clusters, a hallmark of this disease. Methods and results Homozygous PLN-R14del (R14Δ/Δ) mice were randomized to injections with various doses of PLN-ASO (3, 7, 15, or 25 mg/kg) or a scrambled control. Consistent with previous findings, R14Δ/Δ mice exhibited severe cardiac dysfunction, myocardial fibrosis, and aberrant SR clusters by 7 weeks of age. ASO-treated R14Δ/Δ mice displayed a dose-dependent preservation of cardiac function with diminished remodelling and extended lifespan. Correspondingly, abnormal PLN-SR clustering was diminished by ASO therapy in a dose-dependent manner, and SR structure returned to a normal state. Calcium dynamics were investigated separately on isolated cardiomyocytes from treated mice. In wild-type (WT) mice, ASO (25 mg/kg) mediated PLN depletion significantly enhanced calcium and contractile dynamics, confirming effective target engagement. In R14Δ/Δ cardiomyocytes, however, ASO treatment showed limited effects on calcium dynamics. Calcium transient decay and sarcomeric shortening were already enhanced in R14Δ/Δ cardiomyocytes compared to WT, suggesting a partial loss of the PLN-R14del calcium inhibitory function. This pre-existing acceleration of calcium dynamics likely accounts for the limited impact of ASO therapy on calcium regulation in R14Δ/Δ mice.
Conclusions
PLN-ASO treatment demonstrated a dose-dependent restoration of SR organization and a concomitant increase in lifespan in PLN-R14del mice. The enhanced SR calcium uptake in PLN-R14del mice suggests a partial loss of inhibitory function, limiting ASO therapy's effects on calcium dynamics. This implies that PLN-ASO therapy acts predominantly via restoration of SR structure in PLN-R14del cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713 GZ, The Netherlands.
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Ionis Pharmaceuticals, Carlsbad, CA, USA.
ORCID-Profile: Peter van der Meer, Herman H W Silljé
Förderung
- Dutch Heart Foundation
- Fondation Leducq
- PLN Foundation
- China Scholarship Council
- ZonMw
Zitieren
APA
Sun, L., Eijgenraam, T. R., Amilon, C., Janzén, D., Hansson, K. M., Kubli, D. A., Später, D., Mullick, A. E., van der Meer, P., Nunes Teixeira, V. O., & Silljé, H. H. W. (2025). In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment. Cardiovascular Research, 121(13), 2042-2054. https://doi.org/10.1093/cvr/cvaf156
Vancouver
Sun L, Eijgenraam TR, Amilon C, Janzén D, Hansson KM, Kubli DA, et al. In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment. Cardiovascular Research. 2025;121(13):2042-2054. doi:10.1093/cvr/cvaf156
BibTeX
@article{Sun2025,
author = {Sun, Liu and Eijgenraam, Tim R and Amilon, Carl and Janzén, David and Hansson, Kenny M and Kubli, Dieter A and Später, Daniela and Mullick, Adam E and van der Meer, Peter and Nunes Teixeira, Vivian Oliveira and Silljé, Herman H W},
title = {In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment},
journal = {Cardiovascular Research},
year = {2025},
volume = {121},
number = {13},
pages = {2042--2054},
doi = {10.1093/cvr/cvaf156}
}
EUVIMED